This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. International drugmakers are accelerating U.S. investments in an effort to be closer to key markets as tariff pressures complicate global trade and supply chains. Although pharmaceutical imports are exempt from U.S. tariffs, President Donald Trump has made a number of threats on the sector, floating the idea of raising tariffs as high as 250% last month. ...